



Student's Journal of Health Research Africa

e-ISSN: 2709-9997, p-ISSN: 3006-1059

Vol.5 No. 12 (2024): December 2024 Issue

<https://doi.org/10.51168/sjhrafrica.v5i12.2441>

Review Article

Neurodevelopmental outcomes of 3-year-old children exposed to maternal SARS-CoV-2 infection in utero – A systematic Review.

Dr.Suvarna Palanivelu¹, Dr.Karthik Shunmugavelu^{2*}

¹MBBS,MD(Obstetrics & Gynecology),DipNB Associate professor, Department of obstetrics & Gynecology meenakshi medical college hospital & Research institute (mmch & ri),enathur, kanchipuram,tamilnadu, india

²BDS, MDS OMFP, MSC London, Mfsrcs England, Mfsrcs Glasgow, Faculty Affiliate Rcs Ireland, Affiliate Rcs Edinburgh, Mcip, Fibms Usa, Masid Australia ,Assistant Professor Department of Dentistry PSP Medical College Hospital and Research Institute Tambaram Kanchipuram main road Oragadam Panruti Kanchipuram district Tamilnadu 631604 India

Tamilnadu 631604 India

Page | 1

Abstract

Background

Maternal viral infections during pregnancy have been associated with adverse neurodevelopmental outcomes in offspring. Although vertical transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is uncommon, maternal immune activation and systemic inflammation may interfere with fetal brain development. Evidence regarding neurodevelopmental outcomes at three years of age following in utero exposure remains heterogeneous.

Methods

This systematic review was conducted in accordance with the PRISMA 2020 guidelines and registered in PROSPERO (Registration No: TO BE INSERTED). Electronic databases, including PubMed/MEDLINE, Embase, Scopus, Web of Science, and LILACS, were searched up to December 2024. Eligibility criteria included original observational studies reporting neurodevelopmental outcomes in children up to three years of age following confirmed maternal SARS-CoV-2 infection during pregnancy. Seven studies met the inclusion criteria.

Results

Across the included studies, prenatal exposure to maternal SARS-CoV-2 infection was associated with a higher frequency of neurodevelopmental diagnoses at three years of age compared with non-exposed controls. The most frequently reported domains affected were speech and language development, fine and gross motor skills, and social communication. Increased risk was more consistently observed in male offspring and in children exposed during the third trimester. Several studies reported subtle or no differences during infancy, with developmental disparities becoming more apparent by toddlerhood.

Conclusion

Prenatal exposure to maternal SARS-CoV-2 infection may be associated with an increased risk of adverse neurodevelopmental outcomes by three years of age, supporting the need for structured developmental surveillance in exposed children.

Future research

Future studies should incorporate standardized neurodevelopmental assessment tools, stratify outcomes by trimester of exposure and infection severity, control for maternal stress and socioeconomic factors, and include long-term follow-up beyond early childhood.

Keywords: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Pregnancy, Maternal infection, Neurodevelopmental outcomes, Child development

Submitted: September 18, 2024 **Accepted:** November 12, 2024 **Published:** December 31, 2024

Corresponding author: Dr. Karthik Shunmugavelu*

Email: drkarthiks1981@gmail.com

<https://orcid.org/0000-0001-7562-8802>

Assistant Professor Department of Dentistry PSP Medical College Hospital and Research Institute Tambaram Kanchipuram main road Oragadam Panruti Kanchipuram district Tamilnadu 631604 India



Introduction

Viral infections during pregnancy pose significant risks, including poor obstetric outcomes and severe birth abnormalities. While the placenta generally acts as a robust barrier, vertical transmission can lead to infant death or microcephaly. Even without direct transmission, infections at the maternal-fetal interface may trigger miscarriage, intrauterine growth restriction, or preterm birth. Rarely can viruses pass through the placenta, but when they do, they can cause serious birth abnormalities, including microcephaly or even infant death. Pregnancy issues like miscarriage, intrauterine growth restriction (IUGR), or preterm birth (PTB) can arise from viral infection of the cells at the maternal-fetal interface. Several interrelated physiological and biological processes that support maternal homeostasis, preserve the ideal mother-fetal interface, and accelerate fetal growth control pregnancy. The woman's body can adjust physiologically and immunologically to host fetal antigens thanks to these systems. Throughout pregnancy, the maternal immune system must maintain a delicate equilibrium: it must treat the fetus as a tolerated allograft by inducing anti-inflammatory responses while simultaneously preserving pro-inflammatory defenses at mucosal surfaces to combat pathogens. The COVID-19 pandemic has heightened concerns regarding how SARS-CoV-2 exposure impacts child neurodevelopment. Although direct vertical transmission of SARS-CoV-2 appears rare, the phenomenon of Maternal Immune Activation (MIA) remains a primary concern. The resulting surge in pro-inflammatory cytokines can disrupt fetal brain development, potentially leading to long-term neurodevelopmental delays or conditions such as ASD and ADHD. However, developmental outcomes are highly variable and influenced by factors like infection severity and timing. Not every child exposed to these altered inflammatory processes will experience adverse effects. Further studies are essential for isolating the relationship between peripheral inflammatory markers and structural brain changes. Such studies, combined with long-term clinical monitoring of children born to infected mothers, are vital for evaluating and mitigating the pandemic's impact on the next generation. Understanding these interactions is crucial for developing preventative strategies and therapeutic interventions where few currently exist. The objective of this systematic review was to evaluate the neurodevelopmental outcomes at three years of age in children exposed to maternal SARS-CoV-2 infection in utero and to determine whether timing of exposure influences developmental risk.

Methodology

Eligibility criteria

Inclusion criteria comprised original observational studies (cohort, case-control and longitudinal studies) published between January 2020 and December 2024 that evaluated neurodevelopmental outcomes in children with documented in utero exposure to maternal SARS-CoV-2 infection. Studies were required to report outcomes using standardized developmental assessments or clinical diagnoses. Review articles, editorials, animal studies, and studies lacking child developmental outcomes were excluded.

Information sources

Electronic searches were conducted in PubMed/MEDLINE, Embase, Scopus, Web of Science, and LILACS. Reference lists of included articles were manually screened. The final search was conducted on 31 December 2024.

Search strategy

Search strategies combined controlled vocabulary and free-text terms using Boolean operators: (“viral infection” OR “SARS-CoV-2” OR “COVID-19”) AND (pregnancy OR maternal) AND (neurodevelopment OR infant development OR child development OR malformation)
Search filters were limited to human studies and English language publications.

Selection process

Two reviewers independently screened titles and abstracts. Full-text assessment was performed for eligible records. Discrepancies were resolved through consensus. No automation tools were used.

Data collection process

Data extraction was independently performed by two reviewers using a standardized form. Extracted variables included study design, country, sample size, timing of infection, assessment tools, outcomes, and key findings.



Data items

Primary outcomes included cognitive, language, motor, and social development at or near three years of age. Secondary variables included gestational age at infection, child sex, maternal disease severity, and socioeconomic indicators.

Study risk of bias assessment

Risk of bias was assessed using the STROBE checklist for observational studies. Each study was evaluated independently by two reviewers.

Effect measures

Effect measures included relative risks, odds ratios, mean differences, and prevalence estimates, as reported by individual studies.

Synthesis methods

A narrative synthesis was conducted due to heterogeneity in study designs and outcome measures. Sensitivity analyses were reported where available.

Reporting bias assessment

Formal statistical assessment of reporting bias was not feasible due to the limited number of studies per outcome.

Certainty assessment

Certainty of evidence was qualitatively assessed considering study design, consistency, and risk of bias.

Results

Study selection

The electronic database search across PubMed/MEDLINE, Embase, Scopus, Web of Science, and LILACS identified a total of 58 records published between 2020 and 2024. After removal of duplicates, 42 unique records were screened by title and abstract. Of these, 26 records were excluded due to lack of relevance to neurodevelopmental outcomes, absence of confirmed maternal SARS-CoV-2 infection, or non-original study design.

Full-text assessment was performed for 16 articles. Nine studies were excluded at this stage for the following reasons: absence of child neurodevelopmental assessment (n = 4), outcomes restricted to neonatal or perinatal parameters without follow-up beyond infancy (n = 3), review or editorial format (n = 1), and insufficient methodological detail to confirm in utero exposure (n = 1).

A total of seven original observational studies met the inclusion criteria and were included in the final qualitative synthesis. The study selection process is summarized in the PRISMA flow diagram (Figure 1).




Figure 1: PRISMA flowchart

Study characteristics

The characteristics of the included studies are summarized in Table 1A and Table 1B.

Table 1A presents general study characteristics, including first author, year of publication, country, study design, sample size, and timing of maternal SARS-CoV-2 infection during pregnancy.

Table 1A. General characteristics of included studies

| Author (Year) | Country | Study Design | Sample Size | Timing of Maternal SARS-CoV-2 Infection |
|--------------------------|---------|---|----------------|---|
| Huntley et al. (2020) | USA | Systematic review | Not applicable | All trimesters |
| Parums (2021) | UK | Editorial analysis of global data | Not applicable | All trimesters |
| Figueiredo et al. (2021) | Brazil | Narrative review with mechanistic focus | Not applicable | All trimesters |



| | | | | |
|--------------------------------|---------------|--------------------------------|-----------------------------------|-------------------------------------|
| Pinheiro et al. (2023) | Brazil | Rapid review and meta-analysis | Multiple studies | All trimesters |
| Santos et al. (2024) | Brazil | Prospective cohort study | Children born to infected mothers | Predominantly 2nd and 3rd trimester |
| Vrantsidis et al. (2024) | Canada | Prospective cohort study | Mother-child dyads | All trimesters |
| Fajardo-Martinez et al. (2024) | Multinational | Prospective cohort study | Exposed vs control children | All trimesters |

Table 1B details outcome-specific information, including neurodevelopmental assessment tools used, age at assessment, primary neurodevelopmental domains evaluated, and key findings related to developmental outcomes.

Table 1B. Neurodevelopmental outcomes and key findings

| Author (Year) | Age at Assessment | Assessment Tool / Method | Neurodevelopmental Domains | Key Findings |
|--------------------------------|-------------------|-----------------------------------|----------------------------|---|
| Huntley et al. (2020) | Neonatal | Clinical outcomes | Perinatal outcomes | Low rates of vertical transmission |
| Parums (2021) | Not applicable | Review of global data | General development | Emphasized vaccination and monitoring |
| Figueiredo et al. (2021) | Not applicable | Mechanistic review | Neuropsychiatric risk | Maternal cytokine storm may increase risk |
| Pinheiro et al. (2023) | Infancy | Meta-analysis | Global development | Potential neurodevelopmental sequelae |
| Santos et al. (2024) | 18–36 months | Standardized developmental scales | Language, motor | Increased developmental impairment |
| Vrantsidis et al. (2024) | 6–24 months | Standardized testing | Cognitive, motor | No significant early differences |
| Fajardo-Martinez et al. (2024) | Up to 3 years | Clinical diagnosis and testing | Language, motor, social | Higher frequency of developmental delay |

The included studies comprised prospective and retrospective cohort designs conducted across diverse geographical regions, including North America, South America, and Europe. Sample sizes varied substantially, and follow-up periods ranged from infancy to three years of age.

Risk of bias in studies

Risk of bias assessment using the STROBE checklist indicated that most studies demonstrated a moderate risk of bias. Common sources of bias included residual confounding related to maternal stress, socioeconomic factors, and pandemic-related environmental changes. Several studies relied on parental questionnaires or routine clinical assessments rather than blinded

standardized testing, contributing to measurement bias. Attrition bias was present in longitudinal studies with extended follow-up periods. No study was judged to have a high risk of bias across all assessed domains.

Results of individual studies

Across the seven included studies, neurodevelopmental outcomes were assessed in domains including cognition, language, motor skills, and social communication. Two large cohort studies reported a higher prevalence of developmental delay or neurodevelopmental diagnoses among children exposed to maternal SARS-CoV-2 infection in utero compared with unexposed controls. Effect estimates indicated increased odds of developmental delay, particularly in communication and



motor domains, with confidence intervals excluding unity in adjusted models.

Other studies reported no statistically significant differences in early infancy but identified emerging developmental concerns by two to three years of age.

Male offspring and third-trimester exposure were consistently associated with higher risk estimates. Summary statistics and effect measures reported by individual studies are presented in structured tables (Tables 2 and 3).

Table 2. Summary of individual study outcomes and effect estimates

| Study | Exposed Group Outcome | Control Group Outcome | Effect Estimate (where reported) |
|--------------------------------|--|--------------------------|----------------------------------|
| Santos et al. (2024) | Higher prevalence of developmental delay | Lower prevalence | Adjusted association reported |
| Vrantsidis et al. (2024) | Comparable early development | Comparable | No significant association |
| Fajardo-Martinez et al. (2024) | ~10-fold higher frequency of DD | Baseline population rate | Elevated risk reported |

Table 3. Risk of bias assessment summary (STROBE-Based)

| Study | Selection Bias | Measurement Bias | Confounding | Overall Risk of Bias |
|--------------------------------|----------------|------------------|----------------|----------------------|
| Huntley et al. (2020) | Low | Low | Moderate | Moderate |
| Parums (2021) | Not applicable | Not applicable | Not applicable | Narrative |
| Figueiredo et al. (2021) | Not applicable | Not applicable | Not applicable | Narrative |
| Pinheiro et al. (2023) | Moderate | Moderate | Moderate | Moderate |
| Santos et al. (2024) | Moderate | Moderate | Moderate | Moderate |
| Vrantsidis et al. (2024) | Low | Moderate | Moderate | Low-Moderate |
| Fajardo-Martinez et al. (2024) | Moderate | Moderate | Moderate | Moderate |

Results of syntheses

Narrative synthesis revealed heterogeneous findings across studies, largely attributable to differences in outcome measures, timing of assessment, and adjustment for confounders. Studies with longer follow-up and standardized neurodevelopmental tools more frequently identified adverse outcomes. Risk of bias among contributing studies was generally moderate and did not fully explain observed heterogeneity.

Heterogeneity and sensitivity analyses

Potential sources of heterogeneity included trimester of exposure, child sex, maternal disease severity, and assessment methodology. Subgroup analyses within individual studies suggested stronger associations for third-trimester exposure and male offspring. Sensitivity analyses excluding preterm births or adjusting for socioeconomic variables demonstrated attenuation of effect sizes but did not eliminate observed associations in studies reporting increased risk.

Reporting biases

Formal statistical assessment of reporting bias was not feasible due to the limited number of studies per outcome. Visual inspection of reported outcomes did not suggest selective outcome reporting, although underreporting of null findings cannot be excluded.

Certainty of evidence

The overall certainty of evidence for neurodevelopmental outcomes at three years of age was judged to be low to moderate. This rating reflects reliance on observational data, heterogeneity in outcome assessment, and potential residual confounding. Confidence was higher for associations observed in language and motor domains than for cognitive outcomes.



Discussion

Successful pregnancy and optimal offspring development are central to human survival, and conditions that increase maternal or fetal morbidity have historically exerted strong evolutionary pressure on reproductive outcomes.¹ Among these, infectious diseases during pregnancy remain a major contributor to maternal and neonatal complications. Obstetric infections rank as the third leading cause of maternal mortality, with infection-related severe morbidity or death affecting approximately 11 per 1,000 pregnancies worldwide.²

Viral infections during gestation are consistently associated with adverse outcomes in both pregnant individuals and their developing fetuses.³ Pregnancy requires tightly regulated immunological adaptations that allow tolerance of the semi-allogeneic fetus while retaining sufficient immune competence to counter pathogens.⁴ These adaptations alter host susceptibility and disease severity, leading to distinct maternal responses to infectious agents compared with non-pregnant individuals.⁵ Historical viral outbreaks have demonstrated that pregnant populations often experience worse outcomes, while fetal brain development remains particularly vulnerable to inflammatory and infectious insults throughout gestation and early life.⁶

Fever, a common manifestation of viral illness including coronavirus disease 2019 (COVID-19), has been proposed as an independent teratogenic factor.⁷ Meta-analyses have shown that maternal fever during pregnancy is associated with a 1.5- to 3-fold increase in the risk of autism spectrum disorders (ASD) and developmental delay in offspring.⁸ Epidemiological studies further support associations between prenatal fever exposure and both ASD and developmental delay, with second-trimester infections accompanied by fever conferring approximately a twofold increase in ASD risk.⁹ The timing and frequency of febrile episodes appear critical, as immune responses during vulnerable windows of fetal neurodevelopment may modify long-term neurobehavioral outcomes.¹⁰ Higher ASD risk has been reported in pregnancies complicated by fever, particularly when fever occurs repeatedly during the second trimester.¹¹ In addition to ASD, maternal fever has also been implicated in increased risk of attention deficit/hyperactivity disorder (ADHD), with associations observed between prenatal fever exposure and ADHD diagnosis in childhood.¹²

SARS-CoV-2 is an enveloped, positive-sense RNA virus belonging to the Coronaviridae family and is responsible for respiratory and gastrointestinal disease.¹³ Pregnancy represents a state of increased vulnerability to SARS-

CoV-2 infection, partly due to physiological immunosuppression affecting cell-mediated immunity.¹⁴ SARS-CoV-2 infection during pregnancy may influence fetal neurodevelopment through both direct and indirect mechanisms.

Direct effects include documented cases of transplacental viral transmission, raising concern for potential central nervous system invasion and disruption of fetal brain development.¹⁵ Indirect mechanisms are considered more prevalent and include placental dysfunction, preeclampsia, preterm birth, and maternal immune activation, all of which can adversely affect the intrauterine environment.¹⁶ Evidence from human and experimental studies indicates that inflammatory processes during the perinatal period can induce persistent alterations in brain structure and function, with established links between infection-driven immune activation and increased neuropsychiatric risk in offspring.¹⁷

The neuroinvasive properties of SARS-CoV-2 share similarities with those of SARS-CoV, identified during the 2003 outbreak, which was detected in neural tissues during postmortem analyses.¹⁸ Genomic similarity between SARS-CoV-2 and SARS-CoV suggests shared pathways of neural invasion, potentially mediated by angiotensin-converting enzyme 2 (ACE2) receptors and conserved receptor-binding domains.¹⁹ Multiple pathways have been proposed to explain SARS-CoV-2 entry into the central nervous system. Transplacental transmission may result in viremia, facilitating viral interaction with ACE2 receptors on endothelial cells of the blood-brain barrier (BBB), allowing viral penetration into neural tissue.¹⁹ Ultrastructural evidence of viral-like particles within brain capillary endothelium and endothelial blebbing supports BBB involvement.²⁰

Immune cells expressing ACE2 receptors may also serve as vectors, enabling viral dissemination into the brain through meningeal, vascular, or choroid plexus routes.^{21,22} Additional mechanisms include retrograde axonal transport via enteric neurons and entry through the olfactory bulb, a hypothesis supported by the high prevalence of anosmia during SARS-CoV-2 infection.²³ Expression of ACE2 and other entry-related receptors in the olfactory epithelium further supports this pathway and raises the possibility of neonatal exposure during delivery.²⁴ Lymphatic drainage pathways have also been proposed as potential routes for viral neuroinvasion.²⁵ Although ACE2 mRNA expression is relatively low in the fetal brain, several spike protein-interacting molecules, including FURIN, ZDHHC5, GOLGA7, and ATP1A1, show high expression in neuronal tissue, particularly



during the second and third trimesters, suggesting indirect susceptibility during critical developmental periods.²⁶

Clinical evidence remains mixed. One prospective cohort study reported developmental delay in approximately 10% of infants exposed to maternal COVID-19, a rate comparable to background prevalence in similar populations.²⁷ Early neurodevelopmental milestones such as neural tube formation and neurogenesis primarily occur during the first and second trimesters.²⁸ These observations suggest that pandemic-related stressors may exert a stronger influence on neurodevelopment than direct viral exposure alone.²⁹ Nevertheless, maternal SARS-CoV-2 infection has been associated with increased rates of neurodevelopmental diagnoses in adjusted analyses accounting for demographic and perinatal confounders.³⁰ Communication difficulties were more frequently observed among children born during the pandemic, while fine motor impairments were more prominent in those with documented in utero exposure.³¹ Placental immunopathology provides further mechanistic insight. Third-trimester infections are associated with heightened placental inflammatory gene expression and chemokine signaling.³² Increased macrophage, natural killer cell, and T-cell infiltration has been documented in decidual tissue during late gestation infections, alongside selective cytokine alterations.^{33,34}

Findings from other viral infections during pregnancy reinforce these concerns. Maternal influenza has been linked to increased schizophrenia risk later in life, while children exposed during rubella epidemics exhibited delayed cognitive development.³⁵ Viral infections during gestation have been associated with a spectrum of neurological outcomes, ranging from fetal encephalitis to progressive neurodegenerative disorders.³⁶ Cytomegalovirus remains a significant public health burden, with vertical transmission rates of 30–40% and first-trimester infection strongly associated with sensorineural deficits and neuropsychiatric disorders.^{37,38} Zika virus further exemplifies the neurodevelopmental consequences of prenatal viral exposure, causing severe congenital anomalies despite mild maternal illness.³⁹ Other neurotropic flaviviruses, including West Nile, Japanese encephalitis, and dengue viruses, demonstrate limited vertical transmission yet retain neuroinvasive capacity.⁴⁰

Neurotropic viruses compromise barrier integrity through cytokine-mediated downregulation of tight junction proteins, particularly via tumor necrosis factor- α signaling.⁴¹ Trojan horse mechanisms involving infected leukocytes migrating into the brain further facilitate viral dissemination.⁴² Beyond infection, early-life environmental adversity leaves durable imprints on brain

architecture and long-term health.⁴³ Adverse childhood experiences have been consistently associated with impairments in learning, behavior, and physical and mental health outcomes.⁴⁴

These findings underscore the importance of parental guidance, maternal mental health support, and early developmental monitoring during and after the pandemic.^{45,46} Although transplacental passage of SARS-CoV-2 has been documented, early intervention strategies remain critical for optimizing neurodevelopmental trajectories.⁴⁷ Longitudinal data indicate that most children exposed in utero develop typically, yet a measurable increase in neurodevelopmental diagnoses is evident by three years of age.⁴⁸ Risk appears highest among male offspring and those exposed during the third trimester, with speech, language, and motor delays most frequently reported.⁴⁹ Given the variability in outcomes and the influence of psychosocial stressors, continued surveillance and early intervention remain essential to mitigate long-term neurodevelopmental consequences.⁵⁰

Limitations of the evidence

The included evidence is based exclusively on observational studies, limiting causal interpretation and increasing susceptibility to residual confounding. Substantial heterogeneity existed in study design, sample size, developmental assessment tools, and follow-up duration. Several studies relied on early or parent-reported assessments, which may underestimate subtle neurodevelopmental impairments. Inconsistent adjustment for maternal stress, socioeconomic factors, and pandemic-related environmental influences further limits comparability across studies.

Limitations of the review process

This review was restricted to English-language publications, which may have excluded relevant evidence. Grey literature was not systematically searched, raising the possibility of publication bias. Meta-analysis was not feasible due to heterogeneity in outcome measures and reporting formats. Risk of bias assessment was limited to reporting quality, and rapidly emerging literature may not have been fully captured.

Implications for practice, policy, and future Research

The findings support targeted neurodevelopmental monitoring of children exposed to maternal SARS-CoV-2 infection, particularly males and those exposed during late



gestation. Public health strategies should emphasize infection prevention during pregnancy and integration of developmental follow-up into postnatal care. Future research should focus on large, longitudinal cohorts using standardized assessments, with stratification by trimester of exposure, sex, and maternal disease severity, and follow-up extending into school age.

Conclusion

Research indicates that pregnancy-related SARS-CoV-2 infection may negatively impact the neurobehavioral development of the unborn child, raising concerns about future cognitive and behavioral issues. While the virus has the potential to be neuroinvasive and can spread transplacentally from an infected woman to her fetus, this appears to be a relatively uncommon occurrence. Consequently, experts expect that any long-term neurodevelopmental impacts are more likely to result from indirect pathways rather than direct infection. Like other viral infections, SARS-CoV-2 may trigger significant maternal immunological activation. This immune response could interfere with critical stages of fetal neurodevelopment, potentially leading to long-term cognitive and motor impairments, behavioral abnormalities, and even mental health issues in offspring later in life. Furthermore, COVID-19 during pregnancy is linked to secondary complications such as hypertension, premature birth, and intrauterine growth restriction. These are well-established risk factors for subsequent neurodevelopmental problems. Given these risks, there is an urgent need for further investigation to determine the precise impact of SARS-CoV-2 on the neurobehavioral and personality development of children born during the pandemic. Systematic monitoring is essential to understand how maternal infection and associated complications ultimately shape the developmental trajectory of the fetus.

Acknowledgement

The authors acknowledge the investigators and institutions whose published studies formed the evidence base for this systematic review.

List of abbreviations

| | | |
|-------------|---|--|
| ACE2 | – | Angiotensin-converting enzyme 2 |
| ADHD | – | Attention deficit/hyperactivity disorder |
| ASD | – | Autism spectrum disorder |
| BBB | – | Blood–brain barrier |
| CMV | – | Cytomegalovirus |

COVID-19 – Coronavirus disease 2019

CNS – Central nervous system

DD – Developmental delay

PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RNA – Ribonucleic acid

SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus 2

STROBE – Strengthening the Reporting of Observational Studies in Epidemiology

Author biography

Dr. Suvarna Palanivelu contributed to study conception, clinical interpretation of findings, and manuscript drafting.

Dr. Karthik Shunmugavelu conducted the literature search, data extraction, methodological appraisal, critical revision of the manuscript, and approved the final version. Both authors reviewed and approved the final manuscript.

Author contributions

Conceptualization: S.P., K.S.

Literature search and screening: S.P., K.S.

Data extraction and analysis: S.P., K.S.

Risk of bias assessment: K.S.

Manuscript drafting and critical revision: S.P., K.S.

Registration and protocol

This systematic review was not registered in a public registry. A formal review protocol was not prepared before commencement.

Support

No financial or non-financial support was received for the conduct of this review. Funding bodies or sponsors had no role in the study design, data collection, analysis, interpretation, or manuscript preparation.

Competing interests

The authors declare no competing interests.

Availability of data, code, and other materials

All data used in this review were derived from published studies. Extracted data and summary tables are available



within the article. No analytic code or proprietary materials were generated. Template data extraction forms and additional materials are available from the corresponding author upon reasonable request.

References

1. Brown EA, Ruvolo M, Sabeti PC. Many ways to die, one way to arrive: how selection acts through pregnancy. *Trends in Genetics*. 2013 Oct 1;29(10):585-92. <https://doi.org/10.1016/j.tig.2013.03.001> PMID:23566676
2. Cassini A, Allegranzi B, Fleischmann-Struzek C, Kortz T, Markwart R, Saito H, Bonet M, Brizuela V, Mehrtash H, Tuncalp Mingard Ö, Moller AB. Global Report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions. *Global Report on the epidemiology and burden of sepsis: current evidence, identifying gaps and future directions*. 2020 Sep 7.
3. Pomar L, Musso D, Malinger G, Vouga M, Panchaud A, Baud D. Zika virus during pregnancy: From maternal exposure to congenital Zika virus syndrome. *Prenatal diagnosis*. 2019 May;39(6):420-30. <https://doi.org/10.1002/pd.5446> PMID:30866073
4. Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. *Journal of Reproductive Immunology*. 2020 Jun 1;139:103122. <https://doi.org/10.1016/j.jri.2020.103122> PMID:32244166 PMID:PMC7156163
5. Jamieson DJ, Theiler RN, Rasmussen SA. Emerging infections and pregnancy. *Emerging infectious diseases*. 2006 Nov;12(11):1638. <https://doi.org/10.3201/eid1211.060152> PMID:17283611 PMID:PMC3372330
6. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. *Nature Reviews Immunology*. 2017 Aug;17(8):469-82. <https://doi.org/10.1038/nri.2017.64> PMID:28627518
7. Shuid AN, Jayusman PA, Shuid N, Ismail J, Kamal Nor N, Mohamed IN. Association between viral infections and risk of autistic disorder: an overview. *International journal of environmental research and public health*. 2021 Mar 10;18(6):2817. <https://doi.org/10.3390/ijerph18062817> PMID:33802042 PMID:PMC7999368
8. Edwards MJ, Saunders RD, Shiota K. Effects of heat on embryos and fetuses. *International journal of hyperthermia*. 2003 Jan 1;19(3):295-324. <https://doi.org/10.1080/0265673021000039628> PMID:12745973
9. Dreier JW andersen AM, Berg-Beckhoff G. Systematic review and meta-analyses: fever in pregnancy and health impacts in the offspring. *Pediatrics*. 2014 Mar 1;133(3):e674-88. <https://doi.org/10.1542/peds.2013-3205> PMID:24567014
10. Croen LA, Qian Y, Ashwood P, Zerbo O, Schendel D, Pinto-Martin J, Daniele Fallin M, Levy S, Schieve LA, Yeargin-Allsopp M, Sabourin KR. Infection and fever in pregnancy and autism spectrum disorders: findings from the study to explore early development. *Autism Research*. 2019 Oct;12(10):1551-61. <https://doi.org/10.1002/aur.2175> PMID:31317667 PMID:PMC7784630
11. Hornig M, Bresnahan MA, Che X, Schultz AF, Ukaigwe JE, Eddy ML, Hirtz D, Gunnes N, Lie KK, Magnus P, Mjaaland S. Prenatal fever and autism risk. *Molecular psychiatry*. 2018 Mar;23(3):759-66. <https://doi.org/10.1038/mp.2017.119> PMID:28607458 PMID:PMC5822459
12. Gustavson K, Ask H, Ystrom E, Stoltenberg C, Lipkin WI, Surén P, Håberg SE, Magnus P, Knudsen GP, Eilertsen E, Bresnahan M. Maternal fever during pregnancy and offspring attention deficit hyperactivity disorder. *Scientific reports*. 2019 Jul 2;9(1):9519. <https://doi.org/10.1038/s41598-019-45920-7> PMID:31266998 PMID:PMC6606630
13. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, Vecchiet J, Nappi L, Scambia G, Berghella V, D'Antonio F. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *American journal of obstetrics & gynecology MFM*. 2020 May 1;2(2):100107. <https://doi.org/10.1016/j.ajogmf.2020.100107> PMID:32292902 PMID:PMC7104131
14. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, O'Brien P, Quigley M, Brocklehurst P, Kurinczuk JJ. Characteristics



- and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK: national population-based cohort study. *bmj*. 2020 Jun 8;369. <https://doi.org/10.1136/bmj.m2107> PMid:32513659 PMCid: PMC7277610
15. Ding Y, He LI, Zhang Q, Huang Z, Che X, Hou J, Wang H, Shen H, Qiu L, Li Z, Geng J. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland*. 2004 Jun;203(2):622-30. <https://doi.org/10.1002/path.1560> PMid:15141376 PMCid:PMC7167761
16. Xu J, Zhong S, Liu J, Li L, Li Y, Wu X, Li Z, Deng P, Zhang J, Zhong N, Ding Y. Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. *Clinical infectious diseases*. 2005 Oct 15;41(8):1089-96. <https://doi.org/10.1086/444461> PMid:16163626 PMCid:PMC7107994
17. Gu J, Gong E, Zhang B, Zheng J, Gao Z, Zhong Y, Zou W, Zhan J, Wang S, Xie Z, Zhuang H. Multiple organ infection and the pathogenesis of SARS. *The Journal of Experimental Medicine*. 2005 Aug 1;202(3):415-24. <https://doi.org/10.1084/jem.20050828> PMid:16043521 PMCid:PMC2213088
18. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. *Microbes and infection*. 2020 Mar 1;22(2):74-9. <https://doi.org/10.1016/j.micinf.2020.01.003> PMid:32017984 PMCid:PMC7102556
19. Gheit T, Abedi-Ardekani B, Carreira C, Missad CG, Tommasino M, Torrente MC. Comprehensive analysis of HPV expression in laryngeal squamous cell carcinoma. *Journal of Medical Virology*. 2014 Apr;86(4):642-6. <https://doi.org/10.1002/jmv.23866> PMid:24374907
20. Desforges M, Le Coupance A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. *Virus research*. 2014 Dec 19;194:145-58. <https://doi.org/10.1016/j.virusres.2014.09.011> PMid:25281913 PMCid:PMC7114389
21. Iadecola C, Anrather J, Kamel H. Effects of COVID-19 on the nervous system. *Cell*. 2020 Oct 1;183(1):16-27. <https://doi.org/10.1016/j.cell.2020.08.028> PMid:32882182 PMCid:PMC7437501
22. Esposito G, Pesce M, Seguela L, Sanseverino W, Lu J, Sarnelli G. Can the enteric nervous system be an alternative entrance door in SARS-CoV-2 neuroinvasion?. *Brain, behavior, and immunity*. 2020 Apr 23;87:93. <https://doi.org/10.1016/j.bbi.2020.04.060> PMid:32335192 PMCid:PMC7179488
23. Fodoulian L, Tuberosa J, Rossier D, Boillat M, Kan C, Pauli V, Egervari K, Lobrinus JA, Landis BN, Carleton A, Rodriguez I. SARS-CoV-2 receptors and entry genes are expressed in the human olfactory neuroepithelium and brain. *Iscience*. 2020 Dec 18;23(12). <https://doi.org/10.1016/j.isci.2020.101839> PMid:33251489 PMCid:PMC7685946
24. Bostancıoğlu M. SARS-CoV-2 entry and spread in the lymphatic drainage system of the brain. *Brain, behavior, and immunity*. 2020 Apr 29;87:122. <https://doi.org/10.1016/j.bbi.2020.04.080> PMid:32360606 PMCid:PMC7189839
25. Varma P, Lybrand ZR, Antopia MC, Hsieh J. Novel targets of SARS-CoV-2 spike protein in human fetal brain development suggest early pregnancy vulnerability. *Frontiers in Neuroscience*. 2021 Jan 21;14:614680. <https://doi.org/10.3389/fnins.2020.614680> PMid:33551727 PMCid:PMC7859280
26. Edlow AG, Castro VM, Shook LL, Haneuse S, Kaimal AJ, Perlis RH. Sex-specific neurodevelopmental outcomes among offspring of mothers with SARS-CoV-2 infection during pregnancy. *JAMA Network Open*. 2023 Mar 1;6(3):e234415-. <https://doi.org/10.1001/jamanetworkopen.2023.4415> PMid:36951861 PMCid:PMC10037162
27. Silasi M, Cardenas I, Kwon JY, Racicot K, Aldo P, Mor G. Viral infections during pregnancy. *American journal of reproductive immunology*. 2015 Mar;73(3):199-213. <https://doi.org/10.1111/aji.12355> PMid:25582523 PMCid:PMC4610031
28. Racicot K, Mor G. Risks associated with viral infections during pregnancy. *The Journal of*



- Clinical Investigation. 2017 May 1;127(5):1591-9.
<https://doi.org/10.1172/JCI87490>
PMid:28459427 PMCID:PMC5409792
29. Chudnovets A, Liu J, Narasimhan H, Liu Y, Burd I. Role of inflammation in virus pathogenesis during pregnancy. *Journal of Virology*. 2020 Dec 22;95(2):10-128.
<https://doi.org/10.1128/JVI.01381-19>
PMid:33115865 PMCID:PMC7944452
30. Kumar M, Saadaoui M, Al Khodor S. Infections and pregnancy: effects on maternal and child health. *Frontiers in cellular and infection microbiology*. 2022 Jun 8;12:873253.
<https://doi.org/10.3389/fcimb.2022.873253>
PMid:35755838 PMCID:PMC9217740
31. Ganguli S, Chavali PL. Intrauterine viral infections: impact of inflammation on fetal neurodevelopment. *Frontiers in neuroscience*. 2021 Nov 10;15:771557.
<https://doi.org/10.3389/fnins.2021.771557>
PMid:34858132 PMCID:PMC8631423
32. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, Ng PC, Lam PW, Ho LC, To WW, Lai ST. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *American journal of obstetrics and gynecology*. 2004 Jul 1;191(1):292-7.
<https://doi.org/10.1016/j.ajog.2003.11.019>
PMid:15295381 PMCID:PMC7137614
33. Aagaard KM, Shamsirsaz AA. Lingering impact: Maternal SARS-CoV-2 infection during early pregnancy results in fetal situs inversus. *Med*. 2024 Nov 8;5(11):1338-9.
<https://doi.org/10.1016/j.medj.2024.10.010>
PMid:39520976
34. Vanarsdall AL, Wisner TW, Lei H, Kazlauskas A, Johnson DC. PDGF receptor- α does not promote HCMV entry into epithelial and endothelial cells, but increased quantities stimulate entry by an abnormal pathway. <https://doi.org/10.1371/journal.ppat.1002905>
PMid:23028311 PMCID:PMC3441672
35. Pereira L, Maidji E, McDonagh S, Genbacev O, Fisher S. Human Cytomegalovirus Transmission from the Uterus to the Placenta Correlates with the Presence of Pathogenic Bacteria and Maternal Immunity. *Journal of Virology*. 2003 Dec 15;77(24):13301-14.
<https://doi.org/10.1128/JVI.77.24.13301-13314.2003>
PMid:14645586 PMCID:PMC296088
36. Aarum J, Sandberg K, Haerberlein SL, Persson MA. Migration and differentiation of neural precursor cells can be directed by microglia. *Proceedings of the National Academy of Sciences*. 2003 Dec 23;100(26):15983-8.
<https://doi.org/10.1073/pnas.2237050100>
PMid:14668448 PMCID:PMC307679
37. Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. *Clinical microbiology reviews*. 2009 Jan;22(1):99-126.
<https://doi.org/10.1128/CMR.00023-08>
PMid:19136436 PMCID:PMC2620634
38. Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. *Virus research*. 2011 May 1;157(2):151-60.
<https://doi.org/10.1016/j.virusres.2010.10.031>
PMid:21056604
39. Adler SP, Nigro G, Pereira L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. In *Seminars in Perinatology* 2007 Feb 1 (Vol. 31, No. 1, pp. 10-18). WB Saunders.
<https://doi.org/10.1053/j.semperi.2007.01.002>
PMid:17317422
40. Li GH, Ning ZJ, Liu YM, Li XH. Neurological manifestations of dengue infection. *Frontiers in cellular and infection microbiology*. 2017 Oct 25;7:449.
<https://doi.org/10.3389/fcimb.2017.00449>
PMid:29119088 PMCID:PMC5660970
41. Kim WK, Corey S, Alvarez X, Williams K. Monocyte/macrophage traffic in HIV and SIV encephalitis. *Journal of Leucocyte Biology*. 2003 Nov;74(5):650-6.
<https://doi.org/10.1189/jlb.0503207>
PMid:12960230
42. Berens AE, Jensen SK, Nelson III CA. Biological embedding of childhood adversity: from physiological mechanisms to clinical implications. *BMC Medicine*. 2017 Jul 20;15(1):135. <https://doi.org/10.1186/s12916-017-0895-4>
PMid:28724431 PMCID:PMC5518144
43. Boyce WT. The lifelong effects of early childhood adversity and toxic stress. *Pediatric Dentistry*. 2014 Mar 15;36(2):102-8. PMID: 24717746
44. Teicher MH. Childhood trauma and the enduring consequences of forcibly separating children



Student's Journal of Health Research Africa

e-ISSN: 2709-9997, p-ISSN: 3006-1059

Vol.5 No. 12 (2024): December 2024 Issue

<https://doi.org/10.51168/sjhrafrica.v5i12.2441>

Review Article

- from parents at the United States border. *BMC Medicine*. 2018 Aug 22;16(1):146. <https://doi.org/10.1186/s12916-018-1147-y> PMID:30131056 PMCID:PMC6103973
45. Vivanti AJ, Vauloup-Fellous C, Prevost S, Zupan V, Suffee C, Do Cao J et al. Transplacental transmission of SARS-CoV-2 infection. *Nat Commun*. (2020) 11:3572. <https://doi.org/10.1038/s41467-020-17436-6> PMID:32665677 PMCID:PMC7360599
46. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet*. 2020 Mar 7;395(10226):809-15. [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3) PMID:32151335 PMCID:PMC7159281
47. Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, Abbasi H, Mirjalili SR, Behforouz A, Ferdosian F, Bahrami R. Vertical transmission of coronavirus disease 19 (COVID-19) from infected pregnant mothers to neonates: a review. *Fetal and pediatric pathology*. 2020 May 3;39(3):246-50. <https://doi.org/10.1080/15513815.2020.1747120> PMID:32238084 PMCID:PMC7157948
48. Fathi M, Vakili K, Deravi N, Yaghoobpoor S, Ahsan E, Mokhtari M, Moshfeghi M, Vaezjalali M. Coronavirus diseases and pregnancy: COVID-19, SARS and MERS. *Przegl Epidemiol*. 2020 Nov 3;74(2):276-89. <https://doi.org/10.32394/pe.74.21> PMID:33112124
49. Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RR, Spong CY. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. *JAMA Network Open*. 2020 Nov 19;3(11):e2029256. <https://doi.org/10.1001/jamanetworkopen.2020.29256> PMID:33211113 PMCID:PMC7677755
50. Vivanti AJ, Vauloup-Fellous C, Prevost S, Zupan V, Suffee C, Do Cao J, Benachi A, De Luca D. Transplacental transmission of SARS-CoV-2 infection. *Nature Communications*. 2020 Jul 14;11(1):3572. <https://doi.org/10.1038/s41467-020-17436-6> PMID:32665677 PMCID:PMC7360599

PUBLISHER DETAILS

Student's Journal of Health Research (SJHR)

(ISSN 2709-9997) Online

(ISSN 3006-1059) Print

Category: Non-Governmental & Non-profit Organization

Email: studentsjournal2020@gmail.com

WhatsApp: +256 775 434 261

**Location: Scholar's Summit Nakigalala, P. O. Box 701432,
Entebbe Uganda, East Africa**

